Article Summary
A new clinical trial has found that people taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy. The study compared the two blockbuster medications and found that Zepbound was more effective in promoting weight loss. This development has significant implications for the obesity treatment market and could lead to a shift in prescribing practices.
What This Means for You
- If you or someone you know is struggling with obesity, there may soon be a more effective treatment option available.
- Doctors may start prescribing Zepbound more frequently, so it’s essential to be aware of the potential side effects and benefits of this medication.
- With the increased demand for Zepbound, there may be a rise in its price, making it less accessible for some patients.
- Further research is needed to determine the long-term safety and efficacy of Zepbound compared to other obesity treatments.
Original Post
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 16.03% of their body weight, compared to 10.95% for those who took semaglutide, the active ingredient in Wegovy.
Key Terms
- Zepbound
- Wegovy
- Obesity drug
- Tirzepatide
- Semaglutide
- Clinical trial
- Weight loss
ORIGINAL SOURCE:
Source link
